🇺🇸 GLASDEGIB in United States

207 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Febrile Neutropenia — 65 reports (31.4%)
  2. Death — 39 reports (18.84%)
  3. Pneumonia — 24 reports (11.59%)
  4. Sepsis — 15 reports (7.25%)
  5. Electrocardiogram Qt Prolonged — 14 reports (6.76%)
  6. Toxicity To Various Agents — 13 reports (6.28%)
  7. Septic Shock — 11 reports (5.31%)
  8. Neoplasm Progression — 10 reports (4.83%)
  9. Acute Kidney Injury — 8 reports (3.86%)
  10. Hyponatraemia — 8 reports (3.86%)

Source database →

GLASDEGIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GLASDEGIB approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for GLASDEGIB in United States?

Marketing authorisation holder not available in our data.